All In Biotech

Free tool

FAERS Monitor: Daybue

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217026 or its brand name (Daybue, Trofinetide). Reports on generic versions are filed under their own applications.

Reports

6,891

Serious

2,007

29% of reports

Hospitalization

840

Death reported

42

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea3,750
  • underdose2,082
  • vomiting1,187
  • product dose omission issue909
  • seizure882
  • constipation700
  • product use complaint655
  • weight decreased609
  • intentional dose omission484
  • drug ineffective481
  • decreased appetite424
  • nasopharyngitis389
  • flatulence378
  • inappropriate schedule of product administration358
  • faeces soft352

Reports by year received

View as table
YearReports
20201
20231,120
20241,820
20252,524
20261,426

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,268 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
faeces softSignal352155.2139.851,187
product use complaintSignal655132.4122.881,778
underdoseSignal2,08289.686.4177,696
intentional dose omissionSignal48452.748.324,110
seizureSignal88223.522.118,918
flatulenceSignal37820.518.66,954
diarrhoeaSignal3,75017.817.461,083
constipationSignal7009.89.25,580
product dose omission issueSignal9099.58.96,946
vomitingSignal1,1877.77.37,081
weight decreasedSignal6096.76.22,963
nasopharyngitisSignal3896.55.91,799
inappropriate schedule of product administrationSignal3586.15.51,522
decreased appetiteSignal4245.65.11,604
drug ineffective4811.11.06

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.